Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1534-4681
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC ; volume:27 ; number:1 ; day:30 ; month:9 ; year:2019 ; pages:293-300 ; date:1.2020
Annals of surgical oncology ; 27, Heft 1 (30.9.2019), 293-300, 1.2020
- Urheber
-
Graf, Wilhelm
Cashin, Peter H.
Ghanipour, Lana
Enblad, Malin
Botling, Johan
Terman, Alexei
Birgisson, Helgi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1245/s10434-019-07452-2
- URN
-
urn:nbn:de:101:1-2020040904404860325819
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Graf, Wilhelm
- Cashin, Peter H.
- Ghanipour, Lana
- Enblad, Malin
- Botling, Johan
- Terman, Alexei
- Birgisson, Helgi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Laparoscopic Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (L-CRS/HIPEC) for Perforated Low-Grade Appendiceal Mucinous Neoplasm (LAMN II)
Current clinical practices of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Outcomes of minimal access cytoreductive surgery (M-CRS) and HIPEC/EPIC vs. open cytoreductive surgery (O-CRS) and HIPEC/EPIC in patients with peritoneal surface malignancies: a meta-analysis
Serum procalcitonin improves diagnosis of infectious complications after CRS/HIPEC
Implementation of ERAS guidelines in patients undergoing CRS and HIPEC: need for multicentre trial
Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): a Single-Center Experience in Austria
Etiological analysis of infection after CRS + HIPEC in patients with PMP
Early postoperative CRP predicts major complications following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Intraoperative urinary tract resection and construction in CRS + HIPEC procedures: a single center retrospective analysis
Do we still need CRS and HIPEC in colorectal cancer in times of modern chemotherapy and immunotherapy?
Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)
Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy
Laparoscopic Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (L-CRS/HIPEC) for Perforated Low-Grade Appendiceal Mucinous Neoplasm (LAMN II)
Current clinical practices of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Outcomes of minimal access cytoreductive surgery (M-CRS) and HIPEC/EPIC vs. open cytoreductive surgery (O-CRS) and HIPEC/EPIC in patients with peritoneal surface malignancies: a meta-analysis
Serum procalcitonin improves diagnosis of infectious complications after CRS/HIPEC
Implementation of ERAS guidelines in patients undergoing CRS and HIPEC: need for multicentre trial
Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): a Single-Center Experience in Austria
Etiological analysis of infection after CRS + HIPEC in patients with PMP
Early postoperative CRP predicts major complications following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Intraoperative urinary tract resection and construction in CRS + HIPEC procedures: a single center retrospective analysis
Do we still need CRS and HIPEC in colorectal cancer in times of modern chemotherapy and immunotherapy?
Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)
Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy
Laparoscopic Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (L-CRS/HIPEC) for Perforated Low-Grade Appendiceal Mucinous Neoplasm (LAMN II)
Current clinical practices of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Outcomes of minimal access cytoreductive surgery (M-CRS) and HIPEC/EPIC vs. open cytoreductive surgery (O-CRS) and HIPEC/EPIC in patients with peritoneal surface malignancies: a meta-analysis
Serum procalcitonin improves diagnosis of infectious complications after CRS/HIPEC
Implementation of ERAS guidelines in patients undergoing CRS and HIPEC: need for multicentre trial
Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): a Single-Center Experience in Austria
Etiological analysis of infection after CRS + HIPEC in patients with PMP
Early postoperative CRP predicts major complications following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Intraoperative urinary tract resection and construction in CRS + HIPEC procedures: a single center retrospective analysis
Do we still need CRS and HIPEC in colorectal cancer in times of modern chemotherapy and immunotherapy?
Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)